Schreglmann, Sebastian R. http://orcid.org/0000-0002-4129-5808
Wang, David
Peach, Robert L. http://orcid.org/0000-0002-8738-5825
Li, Junheng http://orcid.org/0000-0002-6210-5997
Zhang, Xu http://orcid.org/0000-0003-1988-7767
Latorre, Anna
Rhodes, Edward http://orcid.org/0000-0001-5137-6313
Panella, Emanuele
Cassara, Antonino M. http://orcid.org/0000-0003-3375-7440
Boyden, Edward S.
Barahona, Mauricio http://orcid.org/0000-0002-1089-5675
Santaniello, Sabato http://orcid.org/0000-0002-2133-9471
Rothwell, John http://orcid.org/0000-0003-1367-6467
Bhatia, Kailash P. http://orcid.org/0000-0001-8185-286X
Grossman, Nir
Funding for this research was provided by:
Wellcome Trust
UK Dementia Research Institute
Article History
Received: 20 July 2020
Accepted: 4 December 2020
First Online: 13 January 2021
Competing interests
: N.G., D.W. and E.S.B. have applied for a patent on the ecHT technology, assigned to MIT, and founded a company that utilises it. K.P.B., received funding for travel from GlaxoSmithKline, Orion Corporation, Ipsen, and Merz Pharmaceuticals, LLC; serves on the editorial boards of Movement Disorders and Therapeutic Advances in Neurological Disorders; receives royalties from the publication of Oxford Specialist Handbook of Parkinson’s Disease and Other Movement Disorders (Oxford University Press, 2008); received speaker honoraria from GlaxoSmithKline, Ipsen, Merz Pharmaceuticals, LLC, and Sun Pharmaceutical Industries Ltd.; personal compensation for scientific advisory board for GSK and Boehringer Ingelheim; received research support from Ipsen and from the Halley Stewart Trust through Dystonia Society UK. The rest of the authors declare no competing interests.